Escherichia coli pyruvate dehydrogenase complex is an important component of CXCL10-mediated antimicrobial activity

Infection and Immunity

Volumn 84, Issue 1, 2015, Pages 320-328

  Schutte, Kirsten M ^a   Fisher, Debra J ^a   Burdick, Marie D ^a   Mehrad, Borna ^a   Mathers, Amy J ^a   Mann, Barbara J ^a   Nakamoto, Robert K ^a   Hughes, Molly A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVIC ACID; RECOMBINANT GAMMA INTERFERON INDUCIBLE PROTEIN 10; RECOMBINANT PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; DIHYDROLIPOAMIDE DEHYDROGENASE; OUTER MEMBRANE PROTEIN; PROTEIN BINDING; PYRUVATE DEHYDROGENASE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYTOSOL; ELECTRON MICROSCOPY; ESCHERICHIA COLI K 12; GENE DELETION; GENE DISRUPTION; IMMUNOGOLD LABELING; MOLECULAR LIBRARY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TRANSPOSON; BINDING SITE; ESCHERICHIA COLI; GENE INACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BINDING SITES; CHEMOKINE CXCL10; DIHYDROLIPOAMIDE DEHYDROGENASE; DIHYDROLIPOYLLYSINE-RESIDUE ACETYLTRANSFERASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; GENE KNOCKOUT TECHNIQUES; HUMANS; IMMUNITY, INNATE; PROTEIN BINDING; PYRUVATE DEHYDROGENASE (LIPOAMIDE);

EID: 84957656960     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00552-15     Document Type: Article

References (36)

1. Esche C, Stellato C, Beck LA. 2005. Chemokines: key players in innate and adaptive immunity. J Invest Dermatol 125:615-628. http://dx.doi.org/10.1111/j.0022-202X.2005.23841.x.
2. Crawford MA, Lowe DE, Fisher DJ, Stibitz S, Plaut RD, Beaber JW, Zemansky J, Mehrad B, Glomski IJ, Strieter RM, Hughes MA. 2011. Identification of the bacterial protein FtsX as a unique target of chemokine-mediated antimicrobial activity against Bacillus anthracis. Proc Natl Acad Sci U S A 108:17159-17164. http://dx.doi.org/10.1073/pnas.1108495108.
3. Eliasson M, Egesten A. 2008. Antibacterial chemokines-actors in both innate and adaptive immunity. Contrib Microbiol 15:101-117. http://dx.doi.org/10.1159/000136317.
4. Allen SJ, Crown SE, Handel TM. 2007. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787-820. http://dx.doi.org/10.1146/annurev.immunol.24.021605.090529.
5. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. 2001. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J Immunol 167:623-627. http://dx.doi.org/10.4049/jimmunol.167.2.623.
6. Durr M, Peschel A. 2002. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun 70:6515-6517. http://dx.doi.org/10.1128/IAI.70.12.6515-6517.2002.
7. Zlotnik A, Yoshie O. 2012. The chemokine superfamily revisited. Immunity 36:705-716. http://dx.doi.org/10.1016/j.immuni.2012.05.008.
8. Nomiyama H, Osada N, Yoshie O. 2010. The evolution of mammalian chemokine genes. Cytokine Growth Factor Rev 21:253-262. http://dx.doi.org/10.1016/j.cytogfr.2010.03.004.
9. Moser B, Loetscher P. 2001. Lymphocyte traffic control by chemokines. Nat Immunol 2:123-128. http://dx.doi.org/10.1038/84219.
10. Crawford MA, Burdick MD, Glomski IJ, Boyer AE, Barr JR, Mehrad B, Strieter RM, Hughes MA. 2010. Interferon-inducible CXC chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. PLoS Pathog 6:e1001199. http://dx.doi.org/10.1371/journal.ppat.1001199.
11. Balogh EP, Faludi I, Virok DP, Endresz V, Burian K. 2011. Chlamydophila pneumoniae induces production of the defensin-like MIG/CXCL9, which has in vitro antichlamydial activity. Int J Med Microbiol 301:252-259 http://dx.doi.org/10.1016/j.ijmm.2010.08.020.
12. Crawford MA, Zhu Y, Green CS, Burdick MD, Sanz P, Alem F, O'Brien AD, Mehrad B, Strieter RM, Hughes MA. 2009. Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli. Infect Immun 77:1664-1678. http://dx.doi.org/10.1128/IAI.01208-08.
13. Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, Oppenheim JJ. 2003. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 74:448-455. http://dx.doi.org/10.1189/jlb.0103024.
14. Bals R. 2000. Epithelial antimicrobial peptides in host defense against infection. Respir Res 1:141-150. http://dx.doi.org/10.1186/rr25.
15. Campanella GS, Lee EM, Sun J, Luster AD. 2003. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem 278:17066-17074 http://dx.doi.org/10.1074/jbc.M212077200.
16. Liu B, Wilson E. 2010. The antimicrobial activity of CCL28 is dependent on C-terminal positively-charged amino acids. Eur J Immunol 40:186-196 http://dx.doi.org/10.1002/eji.200939819.
17. Epand RM, Vogel HJ. 1999. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11-28. http://dx.doi.org/10.1016/S0005-2736(99)00198-4.
18. Chen H, Xu Z, Peng L, Fang X, Yin X, Xu N, Cen P. 2006. Recent advances in the research and development of human defensins. Peptides 27:931-940. http://dx.doi.org/10.1016/j.peptides.2005.08.018.
19. Mathers AJ, Cox HL, Kitchel B, Bonatti H, Brassinga AK, Carroll J, Scheld WM, Hazen KC, Sifri CD. 2011. Molecular dissection of an outbreak of carbapenem-resistant Enterobacteriaceae reveals intergenus KPC carbapenemase transmission through a promiscuous plasmid. mBio 2:e00204-11. http://dx.doi.org/10.1128/mBio.00204-11.
20. Mathers AJ, Peirano G, Pitout JD. 2015. Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 90:109-154. http://dx.doi.org/10.1016/bs.aambs.2014.09.002.
21. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2:2006.0008.
22. Cherepanov PP, Wackernagel W. 1995. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158:9-14. http://dx.doi.org/10.1016/0378-1119(95)00193-A.
23. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manualsource>. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
24. Dower WJ, Miller JF, Ragsdale CW. 1988. High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 16:6127-6145 http://dx.doi.org/10.1093/nar/16.13.6127.
25. Zemansky J, Kline BC, Woodward JJ, Leber JH, Marquis H, Portnoy DA. 2009. Development of a mariner-based transposon and identification of Listeria monocytogenes determinants, including the peptidyl-prolyl isomerase PrsA2, that contribute to its hemolytic phenotype. J Bacteriol 191:3950-3964. http://dx.doi.org/10.1128/JB.00016-09.
26. Yi H, Leunissen J, Shi G, Gutekunst C, Hersch S. 2001. A novel procedure for pre-embedding double immunogold-silver labeling at the ultrastructural level. J Histochem Cytochem 49:279-284. http://dx.doi.org/10.1177/002215540104900301.
27. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing: 25th informational supplement (M100-S25), p 238. Clinical and Laboratory Standards Institute, Wayne, PA.
28. Misra RV, Horler RS, Reindl W, Goryanin II, Thomas GH. 2005. EchoBASE: an integrated post-genomic database for Escherichia coli. Nucleic Acids Res 33:D329-D333.
29. de Kok A, Hengeveld AF, Martin A, Westphal AH. 1998. The pyruvate dehydrogenase multi-enzyme complex from Gram-negative bacteria. Biochim Biophys Acta 1385:353-366. http://dx.doi.org/10.1016/S0167-4838(98)00079-X.
30. Riley M. 1993. Functions of the gene products of Escherichia coli. Microbiol Rev 57:862-952.
31. Neveling U, Bringer-Meyer S, Sahm H. 1998. Gene and subunit organization of bacterial pyruvate dehydrogenase complexes. Biochim Biophys Acta 1385:367-372. http://dx.doi.org/10.1016/S0167-4838(98)00080-6.
32. Kim J, Copley SD. 2007. Why metabolic enzymes are essential or nonessential for growth of Escherichia coli K12 on glucose. Biochemistry 46: 12501-12511. http://dx.doi.org/10.1021/bi7014629.
33. Todar K. 2012. Todar's online textbook of bacteriology, p 1-4. University of Wisconsin-Madison Department of Bacteriology, Madison, WI. http://textbookofbacteriology.net/metabolism.html.
34. Magnuson K, Jackowski S, Rock CO, Cronan JE, Jr. 1993. Regulation of fatty acid biosynthesis in Escherichia coli. Microbiol Rev 57:522-542.
35. Wolfe AJ. 2005. The acetate switch. Microbiol Mol Biol Rev 69:12-50. http://dx.doi.org/10.1128/MMBR.69.1.12-50.2005.
36. Chang YY, Cronan JE, Jr. 1983. Genetic and biochemical analyses of Escherichia coli strains having a mutation in the structural gene (poxB) for pyruvate oxidase. J Bacteriol 154:756-762.